Time filter

Source Type

Conning Towers-Nautilus Park, CT, United States

Van Zandt M.C.,Institutes for Pharmaceutical Discovery LLC | Whitehouse D.L.,Institutes for Pharmaceutical Discovery LLC | Golebiowski A.,Institutes for Pharmaceutical Discovery LLC | Ji M.K.,Institutes for Pharmaceutical Discovery LLC | And 16 more authors.
Journal of Medicinal Chemistry | Year: 2013

Recent efforts to identify treatments for myocardial ischemia reperfusion injury have resulted in the discovery of a novel series of highly potent α,α-disubstituted amino acid-based arginase inhibitors. The lead candidate, (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid, compound 9, inhibits human arginases I and II with IC50s of 223 and 509 nM, respectively, and is active in a recombinant cellular assay overexpressing human arginase I (CHO cells). It is 28% orally bioavailable and significantly reduces the infarct size in a rat model of myocardial ischemia/reperfusion injury. Herein, we report the design, synthesis, and structure-activity relationships (SAR) for this novel series of inhibitors along with pharmacokinetic and in vivo efficacy data for compound 9 and X-ray crystallography data for selected lead compounds cocrystallized with arginases I and II. © 2013 American Chemical Society. Source

Discover hidden collaborations